Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Speedy development drives Magainin strategy

Speedy development drives Magainin strategy

Magainin Pharmaceuticals Inc., one of a growing number of biotech companies taking a new look at the antibiotics market, has sought to lower its risk by systematically focusing itself on projects that can undergo speedy development and approval.

The company is developing new classes of anti-infectives derived from host defense systems. "By taking a development focus, everything that we do is geared to how we can get

Read the full 733 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers